Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients

Dermatology. 2015;231(2):127-33. doi: 10.1159/000381849. Epub 2015 Jun 27.

Abstract

Background: BRAF mutation frequencies in melanoma subtypes have clinical implications and offer pathogenetic clues.

Objectives: To characterize BRAF mutation status in melanoma of unknown primary (MUP) patients, in histological melanoma subtypes and by localization of primary tumors.

Methods: In 179 patients with stage IV metastatic melanoma, BRAF mutation status, histological subtype and localization of primary (except for 29 MUP patients) were analyzed.

Results: BRAF mutations were found in 44.3%, of which 80.5% were BRAF V600E and 19.5% showed non-V600E BRAF mutations. BRAF mutation frequency depended on histological subtype (57.4% superficial spreading melanoma, 54.7% nodular melanoma, 11.1% mucosal melanoma, 28.6% acral lentiginous melanoma) and concerning non-V600E BRAF mutations on localization of primary. In MUP the BRAF mutation pattern resembled superficial spreading and nodular melanomas.

Conclusion: BRAF mutation frequencies depend on histological subtype and localization of primary melanoma. Non-V600E BRAF mutations mostly occur in patients with primaries on 'head and neck' as well as 'trunk' but not on 'extremities'.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Extremities
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / pathology
  • Humans
  • Melanoma / genetics*
  • Melanoma / pathology
  • Melanoma / secondary
  • Mucous Membrane
  • Mutation Rate
  • Neoplasm Staging
  • Neoplasms, Unknown Primary / genetics*
  • Neoplasms, Unknown Primary / pathology
  • Proto-Oncogene Proteins B-raf / genetics*
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / secondary
  • Torso

Substances

  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf